As of November 6, 2026, OKYO Pharma LTD is a publicly traded company (Nasdaq: OKYO); its largest reported holder is Chernett Jorey, with 9.5% on Schedule 13G/A of February 13, 2026, then Sirenia Capital Management LP (7.7%) (Schedule 13G/A, February 13, 2026).
Is this your company?
About to sign with, pay or invest in OKYO Pharma LTD? See the free Snapshot first.
Free to see. No signup.
Is OKYO Pharma LTD a real, registered company?
- OKYO Pharma LTD files with the SEC under CIK 1849296 (its SEC filings).
- Its shares are listed under the ticker OKYO on Nasdaq (SEC company record).
- business address in London, X0, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under OKYO Pharma LTD in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Woodline Partners LP (filed 2026-05-15).
Who are OKYO Pharma LTD's owners and officers?
OKYO Pharma LTD: business address in London, X0; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-05-15).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-05-15 | Woodline Partners LP | 7% |
| Schedule 13G, 2026-05-15 | Sirenia Capital Management LP | 7.7% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 0% |
| Schedule 13G, 2026-02-18 | Point72 Asset Management, L.P. | 7.9% |
| Schedule 13G/A, 2026-02-13 | Chernett Jorey | 9.5% |
| Schedule 13G/A, 2026-02-12 | Dauntless Investment Group, LLC | 1.2% |
| Schedule 13G/A, 2025-11-14 | Chernett Jorey | 7.8% |
| Schedule 13G/A, 2025-11-14 | Dauntless Investment Group, LLC | 6.3% |
| Schedule 13G, 2025-10-29 | Laura Natalia Monica Fonda | 5.01% |
| Schedule 13G/A, 2025-08-05 | Dauntless Investment Group, LLC | 7.3% |
Questions about who owns OKYO Pharma LTD
Who owns OKYO Pharma LTD?
On this page, 4 holders' latest ownership filings report 5% or more of OKYO Pharma LTD: Chernett Jorey (9.5%, Schedule 13G/A, filed 2026-02-13), Sirenia Capital Management LP (7.7%, Schedule 13G, filed 2026-05-15), Woodline Partners LP (7%, Schedule 13G, filed 2026-05-15) and Laura Natalia Monica Fonda (5.01%, Schedule 13G, filed 2025-10-29).
Who are the largest shareholders of OKYO Pharma LTD?
By the share each holder's latest filing reports, the largest holders of OKYO Pharma LTD on this page are Chernett Jorey (9.5%), Sirenia Capital Management LP (7.7%) and Woodline Partners LP (7%).
When did Chernett Jorey buy into OKYO Pharma LTD?
The filings give report dates, not purchase dates. The earliest filing from Chernett Jorey on this page is the Schedule 13G/A, filed 2025-11-14, reporting 7.8%; its latest, Schedule 13G/A filed 2026-02-13, reports 9.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on OKYO Pharma LTD?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on OKYO Pharma LTD: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OKYO Pharma LTD covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own OKYO Pharma LTD shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 10,851,416 shares (20.7% of shares outstanding), held indirectly through Via Panetta Partners Limited (Form 4/A, 2026-08-07).
- , the chief development officer and a director: 112,420 shares (0.21% of shares outstanding) (Form 4/A, 2026-08-07).
- , a director: 35,201 shares (0.07% of shares outstanding) (Form 4/A, 2026-08-07).
- , the chief scientific officer: 20,030 shares (0.04% of shares outstanding) (Form 4/A, 2026-08-07).
- , the chief medical officer: 20,000 shares (0.04% of shares outstanding) (Form 4/A, 2026-08-07).
Shares outstanding: 52,479,527 as of 2026-07-15, from the company's latest SEC cover page.
How much has OKYO Pharma LTD raised?
No fundraising or offering filing from OKYO Pharma LTD is on file with us.
Keep reading
More on OKYO Pharma LTD and the records around it.
OKYO Pharma LTD elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- Dauntless Investment Group, LLC also filed stake reports on 3 other companies: KAZIA THERAPEUTICS LTD (Oct 2026), Azitra, Inc. (Jun 2026), FEMASYS INC (Nov 2025)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/okyo-pharma